LIXT
Lixte Biotechnology Holdings, Inc.NASDAQHealthcare$2.88-5.57%ClosedMarket Cap: $13.1M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.01
P/S
0.00
EV/EBITDA
0.79
DCF Value
$84.13
FCF Yield
-23433.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-251.4%
ROA
-47.7%
ROIC
-42.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-5.10B | $-6.08B | $-0.35 | — |
| FY 2025 | $0.00 | NaN% | $-5.11B | $-6.08B | $-1.26 | — |
| Q3 2025 | $0.00 | NaN% | $-1.8M | $-2.0M | $-0.33 | — |
| Q2 2025 | $0.00 | NaN% | $-774.8K | $-775.7K | $-0.29 | — |
| Q1 2025 | $0.00 | NaN% | $-706.9K | $-709.6K | $-0.29 | — |
| Q4 2024 | $0.00 | NaN% | $-613.5K | $-617.7K | $-0.27 | — |
| FY 2024 | $0.00 | NaN% | $-3.6M | $-3.6M | $-1.59 | — |
| Q3 2024 | $0.00 | NaN% | $-983.3K | $-986.0K | $-0.44 | — |
| Q2 2024 | $0.00 | NaN% | $-1.0M | $-1.0M | $-0.45 | — |
| Q1 2024 | $0.00 | NaN% | $-966.9K | $-971.3K | $-0.43 | — |
| Q4 2023 | $0.00 | NaN% | $-1.0M | $-1.0M | $-0.46 | — |
| FY 2023 | $0.00 | NaN% | $-5.1M | $-5.1M | $-2.66 | — |